Home  »  Finance   »  Here’s Why Horizon Therapeutics Public Limited C...

Here’s Why Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) Is An Attractive Investment Right Now

The trading price of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) floating lower at last check on Wednesday, May 24, closing at $100.06, -0.04% lower than its previous close.

Traders who pay close attention to intraday price movement should know that it has been fluctuating between $99.93 and $101.14. The company’s P/E ratio in the trailing 12-month period was 63.11, while its 5Y monthly beta was 1.12. In examining the 52-week price action we see that the stock hit a 52-week high of $113.83 and a 52-week low of $57.84. Over the past month, the stock has lost -9.51% in value.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


Horizon Therapeutics Public Limited Company, whose market valuation is $23.09 billion at the time of this writing, is expected to release its quarterly earnings report May 03, 2023. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $1.12 per share this quarter, however they have predicted annual earnings per share of $5.24 for 2023 and $7.07 for 2024. It means analysts are expecting annual earnings per share growth of 7.80% this year and 34.90% next year.

Analysts have forecast the company to bring in revenue of $915.71 million for the current quarter, with the likely lows of $906.31 million and highs of $922.34 million. The average estimate suggests sales will likely up by 4.50% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2023 is $3.87 billion. The company’s revenue is forecast to grow by 6.60% over what it did in 2023.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Horizon Therapeutics Public Limited Company No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest HZNP has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a Hold, while an average of long term indicators suggests that the stock is currently Hold.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned HZNP a recommendation rating is 6. Out of them, 5 rate it a Hold, while 1 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Horizon Therapeutics Public Limited Company (HZNP) as Underweight, while 0 advise Sell. Analysts have rated the stock Hold, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 12.62, which symbolizes a positive outlook. A quick review shows that HZNP’s price is currently -7.15% off the SMA20 and -8.12% off the SMA50. The RSI metric on the 14-day chart is currently showing 33.21, and weekly volatility stands at 2.05%. When measured over the past 30 days, the indicator reaches 1.56%. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)’s beta value is currently sitting at 1.12, while the Average True Range indicator is currently displaying 2.34. With analysts defining $116.50-$116.50 as the low and high price targets, we arrive at a consensus price target of $116.50 for the trailing 12-month period. The current price is about -16.43% off the estimated low and -16.43% off the forecast high, based on this estimate. Investors will be thrilled if HZNP’s share price rises to $116.50, which is the median consensus price. At that level, HZNP’s share price would be -16.43% below current price.

To see how Horizon Therapeutics Public Limited Company stock has been performing today in comparison to its peers in the industry, here are the numbers: HZNP stock’s performance was -0.04% at last check in today’s session, and 14.51% in the past year, while Pfizer Inc. (PFE) has been trading -1.06% in recent session and positioned -25.83% lower than it was a year ago. Another comparable company GSK plc (GSK) saw its stock trading -1.57% lower in today’s session but was down -23.47% in a year. Horizon Therapeutics Public Limited Company has a P/E ratio of 63.11, compared to Pfizer Inc.’s 7.81 and GSK plc’s 12.95. Also during today’s trading, the S&P 500 Index has plunged -0.74%, while the Dow Jones Industrial also saw a negative session, down -0.59% today.

An evaluation of the daily trading volume of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) indicates that the 3-month average is 2.31 million. However, this figure has increased over the past 10 days to an average of 5.21 million.

Currently, records show that 228.40 million of the company’s shares remain outstanding. The insiders hold 1.17% of outstanding shares, whereas institutions hold 95.80%. The stats also highlight that short interest as of Apr 27, 2023, stood at 6.57 million shares, resulting in a short ratio of 3.78 at that time. From this, we can conclude that short interest is 2.87% of the company’s total outstanding shares. It is noteworthy that short shares in April were up slightly from the previous month’s figure, which was 3.77 million. However, since the stock’s price has seen -12.07% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.

Leave a Comment

Your email address will not be published. Required fields are marked *